173 related articles for article (PubMed ID: 27987156)
1. Immunotherapy of Uveal Melanoma: Vaccination Against Cancer.
Kummer M; Schuler-Thurner B
Methods Mol Biol; 2017; 1499():273-278. PubMed ID: 27987156
[TBL] [Abstract][Full Text] [Related]
2. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma].
Schuler-Thurner B; Bartz-Schmidt KU; Bornfeld N; Cursiefen C; Fuisting B; Grisanti S; Heindl LM; Holbach L; Keserü M; Knorr H; Koch K; Kruse F; Meiller R; Metz C; Meyer-ter-Vehn T; Much M; Reinsberg M; Schliep S; Seitz B; Schuler G; Süsskind D; Viestenz A; Wagenfeld L; Zeschnigk M
Ophthalmologe; 2015 Dec; 112(12):1017-21. PubMed ID: 26602097
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of uveal melanoma.
Bosch JJ
Dev Ophthalmol; 2012; 49():137-149. PubMed ID: 22042018
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.
Bol KF; van den Bosch T; Schreibelt G; Mensink HW; Keunen JE; Kiliç E; Japing WJ; Geul KW; Westdorp H; Boudewijns S; Croockewit SA; van Rossum MM; de Goede AL; Naus NC; van der Graaf WT; Gerritsen WR; de Klein A; Punt CJ; Figdor CG; Cohen VM; Paridaens D; de Vries IJ
Ophthalmology; 2016 Oct; 123(10):2265-7. PubMed ID: 27476772
[No Abstract] [Full Text] [Related]
6. Immunotherapy of uveal melanoma.
Ksander BR; Chen PW
Dev Ophthalmol; 1999; 30():220-30. PubMed ID: 10627926
[No Abstract] [Full Text] [Related]
7. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
8. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.
Bol KF; Mensink HW; Aarntzen EH; Schreibelt G; Keunen JE; Coulie PG; de Klein A; Punt CJ; Paridaens D; Figdor CG; de Vries IJ
Am J Ophthalmol; 2014 Nov; 158(5):939-47. PubMed ID: 25038326
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives.
Kaštelan S; Antunica AG; Oresković LB; Pelčić G; Kasun E; Hat K
Curr Med Chem; 2020; 27(8):1350-1366. PubMed ID: 31272342
[TBL] [Abstract][Full Text] [Related]
10. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Jindal V
Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
[TBL] [Abstract][Full Text] [Related]
11. Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases.
Jager MJ; Dogrusöz M; Woodman SE
Asia Pac J Ophthalmol (Phila); 2017; 6(2):179-185. PubMed ID: 28399339
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Immune interactions: implications for cancer therapy.
Tham M; Abastado JP
Cell Cycle; 2015; 14(9):1347-8. PubMed ID: 25894850
[No Abstract] [Full Text] [Related]
13. Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes?
Jager MJ; Ly LV; El Filali M; Madigan MC
Prog Retin Eye Res; 2011 Mar; 30(2):129-46. PubMed ID: 21129496
[TBL] [Abstract][Full Text] [Related]
14. Update on Metastatic Uveal Melanoma: Progress and Challenges.
Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory cell infiltrates in advanced metastatic uveal melanoma.
Krishna Y; McCarthy C; Kalirai H; Coupland SE
Hum Pathol; 2017 Aug; 66():159-166. PubMed ID: 28655639
[TBL] [Abstract][Full Text] [Related]
16. [Characteristics of the immune status of patients with uveal melanoma during the performance of organ-preserving treatment].
Maletskiĭ AP; Vit VV; Vanichkin AA
Oftalmol Zh; 1989; (6):341-6. PubMed ID: 2622598
[TBL] [Abstract][Full Text] [Related]
17. Changes in immunological markers and influx of macrophages following trans-scleral thermotherapy of uveal melanoma.
Dennaoui J; Bronkhorst IH; Ly LV; de Wolff-Rouendaal D; Keunen JE; Schalij-Delfos NE; Jager MJ
Acta Ophthalmol; 2011 May; 89(3):268-73. PubMed ID: 21232082
[TBL] [Abstract][Full Text] [Related]
18. Effect of an anti-CD54 (ICAM-1) monoclonal antibody (UV3) on the growth of human uveal melanoma cells transplanted heterotopically and orthotopically in SCID mice.
Wang S; Coleman EJ; Pop LM; Brooks KJ; Vitetta ES; Niederkorn JY
Int J Cancer; 2006 Feb; 118(4):932-41. PubMed ID: 16152588
[TBL] [Abstract][Full Text] [Related]
19. Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma.
Venza M; Visalli M; Catalano T; Beninati C; Teti D; Venza I
Anticancer Agents Med Chem; 2017; 17(2):190-205. PubMed ID: 27109020
[TBL] [Abstract][Full Text] [Related]
20. Uveal melanoma.
Kashyap S; Meel R; Singh L; Singh M
Semin Diagn Pathol; 2016 May; 33(3):141-7. PubMed ID: 26972224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]